Argatroban business in Europe transferred to Ethypharm

Japanese drugmaker Mitsubishi Tanabe Pharma (MTPC) has entered into an agreement with Paris, France-based Ethypharm for the transfer of the business of the selective antithrombin agent, argatroban monohydrate in Europe.

Under MTPC's strategic focus on Radicava (edaravone), a treatment for amyotrophic lateral sclerosis, within its European operations, it has been decided to transfer the argatroban business to Ethypharm. No financial terms of the accord have been disclosed.

In Europe, MTPC’s subsidiary, Mitsubishi Tanabe Pharma Europe (MTPE), located in London, UK, and MTPE's subsidiary, Mitsubishi Tanabe Pharma, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in UK and Germany, among other European countries, through their respective networks of partners.